Starting on April 20, Cannalogue, a Toronto-based health and technology company, will begin offering CBD flower from $1.96/gram, per a company press release.

According to Cannalogue, it is the lowest per gram price for medical cannabis in Canada

“We are living in times of unprecedented financial need, where cost is the key determinant in health decisions,” Cannalogue president and CEO, Dr. Mohan Cooray, said in the release. “With the lack of reasonable coverage, Cannalogue is doing all that we can to help our patients, and today is a gigantic leap forward in the quest towards affordable medical cannabis access for all Canadians.”

Members enrolled in the company’s Compassionate Care Program will be eligible to purchase the flower. All of the products available — from flower to oils, capsules and topicals — are from licenced Health Canada producers.

Dr. Cooray confirmed with The GrowthOp that one variety of CBD flower will be available for $1.96/gram but a range of other products are available for up to 50 per cent off.

“More producers are coming on board and reducing prices, so we should have lots more selection at that price point,” he said, adding that Cannalogue has the most “inclusive compassionate program in the country.”

According to the company’s website, qualified groups include front-line workers, seniors (aged 60+), veterans, Indigenous peoples, first responders, nurses and teachers, among other groups. Those with an annual income of less than $70,000 per year can also qualify for the program.

Last September, Cannalogue created a petition calling for national cannabis coverage and improved access for medical patients.

“These are some of the most challenging times for Canadians — especially those who suffer from chronic conditions such as pain or anxiety,” Dr. Cooray said at the time. “Removing the barriers that prevent access to medical cannabis is the fundamental goal of Cannalogue and this petition will help us ensure that disadvantaged groups, including those below the poverty line, get the medications they need.”

The company launched in 2020 and its origins trace back to Dr. Cooray’s post-graduate studies in internal medicine at McMaster University, where he first noticed the therapeutic potential of medical cannabis.

“When I started my practice, over five years ago, I was very skeptical about the role, if any, of cannabinoids in digestive diseases. I didn’t think this stuff worked at all,” he told The GrowthOp last March.

However, after witnessing his patients’ success in using cannabis to treat conditions like inflammatory bowel disease, Crohn’s disease and ulcerative colitis, he changed his mind.

“The outcomes that I was seeing were exceptional,” he said.